Purchase Order HHSN261201700089A

Ended Awarded Last action

Contract number
HHSN261201700089A
Awardee
Awarding agency
Obligated
$117,038

Award facts

Opportunity
Contract value 100% obligated
$117,038.40 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
621511 Medical Laboratories
PSC
Q301 Reference Laboratory Testing
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
China

Award details come from SAM.gov/FPDS.

About this award

The National Cancer Institute awarded a purchase order to Novogene Corporation Inc. for $117,038.40 on September 22, 2017, to provide laboratory services analyzing fresh-frozen tissue samples from a lung cancer study conducted in Xuanwei, China. The order is firm fixed price with no set-aside designation. Work is performed in China and concludes March 31, 2018. Novogene is a minority-owned small business based in Sacramento, California, specializing in genomic sequencing and bioinformatics services.

Quick answers

Who was awarded contract HHSN261201700089A?

HHSN261201700089A was awarded to Novogene Corporation Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2017.

How much is contract HHSN261201700089A worth?

The government has obligated $117,038 on HHSN261201700089A.

Was contract HHSN261201700089A competed?

The extent of competition for HHSN261201700089A was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award